Table 1. . Patient characteristics in bevacizumab-naive and bevacizumab-refractory groups.
| Patient characteristics | Bev-naive group 1 (n = 73) | Bev-refractory group 2 (n = 25) | |
|---|---|---|---|
| Rindo + bev (n = 36) | Control + bev (n = 37) | ||
| Age, years: | |||
| – Median (range) | 59 (44–79)† | 55 (30–75) | 58 (39–79) |
| – ≥50 years, n (%) | 35 (97%)† | 27 (73%) | 15 (75%) |
| Sex, n (%): | |||
| – Female | 17 (47%) | 15 (41%) | 9 (36%) |
| – Male | 19 (53%) | 22 (59%) | 16 (64%) |
| KPS (%): | |||
| – ≥80 | 80.5%‡ | 81% | 56% |
| – <80 | 19.4%‡ | 18.9% | 44% |
| Recurrence, n (%): | |||
| – 1st | 33 (92%)§ | 28 (76%) | 4 (16%) |
| – 2nd | 3 (8%)§ | 9 (24%) | 21 (84%) |
| Surgery after last recurrence, n (%): | |||
| – Gross total resection | 14 (39%)§ | 6 (16%) | 3 (15%) |
| – Subtotal resection/biopsy/unspecified | 1 (3%)§ | 4 (11%) | 2 (10%) |
| Primary GBM, n (%) | 35 (97%)‡ | 35 (95%) | 25 (100%) |
| On steroids at study entry, n (%) | 18 (50%)‡ | 19 (51%) | 7 (28%) |
| Time from diagnosis to study day 1, months, median (range) | 10.8 (3.7–55.2)§ | 11.6 (4.7–38.3) | 16 (8.4–58.6) |
Symbols are present to depict weighted favorability of characteristics toward rindopepimut-treated subgroup as compared with control-treated subgroup within group 1. The symbols are not intended to demonstrate a statistically calculated weight.
†Favors rindopepimut.
‡Even distribution.
§Favors control.
Bev: Bevacizumab; KPS: Karnofsky performance status; Rindo: Rindopepimut.